Viewing Study NCT05984602


Ignite Creation Date: 2025-12-25 @ 3:46 AM
Ignite Modification Date: 2025-12-26 @ 2:32 AM
Study NCT ID: NCT05984602
Status: RECRUITING
Last Update Posted: 2025-04-15
First Post: 2023-08-02
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
Sponsor: NYU Langone Health
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module